- PureTech Founded Entity Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
- Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
- Karuna Therapeutics Announces Proposed Public Offering of Common Stock
- Karuna Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides General Business Update
- PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia
- Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia
- PureTech Receives Approximately $118 Million from Sale of Portion of Founded Entity Shares
- Karuna Therapeutics to Participate at 10th Annual SVB Leerink Global Healthcare Conference
- PureTech Adds Bharatt Chowrira, PureTech’s President and Chief of Business and Strategy, to Board of Directors
- Karuna Therapeutics Announces Appointment of Ronald Marcus, M.D., as Senior Vice President of Medical
More ▼
Key statistics
As of last trade Karuna Therapeutics Inc (KRTX:NMQ) traded at 124.42, -15.34% below its 52-week high of 146.97, set on Feb 09, 2021.
52-week range
Markit short selling activity
Open | 119.00 |
---|---|
High | 130.05 |
Low | 118.10 |
Bid | 123.42 |
Offer | 124.22 |
Previous close | 124.77 |
Average volume | 200.73k |
---|---|
Shares outstanding | 27.02m |
Free float | 23.89m |
P/E (TTM) | -- |
Market cap | 3.37bn USD |
EPS (TTM) | -1.99 USD |
Data delayed at least 15 minutes, as of Mar 02 2021 20:16 GMT.
More ▼